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During the past decade, in Finland and elsewhere, biomedicine and genomics-related 
initiatives have been organized under the sociotechnical imaginary of personalized medicine. 
Within this imaginary, the medical future is promoted and made up, and the activities often 
subtly change the very meaning of what the imaginary of personalized medicine entails. In 
this paper, we study the Finnish strategies and pursuits addressing the utilization of genomics 
to advance personalized medicine. We build our analysis on previous research on 
sociotechnical imaginaries (Jasanoff & Kim, 2015) and the hype and expectations 
surrounding emerging technologies (Brown, 2003; Brown & Michael, 2003; Borup et al., 
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2006). We emphasize that the sociotechnical imaginary requires practical maintenance. In our 
analysis we address both rhetorical and action framings related to the making of personalized 
medicine and point out that activities of maintenance simultaneously pursue and reconfigure 
the imaginary of personalized medicine. Furthermore, our analysis shows that the focus of 
advocacy in personalized medicine has shifted from the promise of health to the promise of 
wealth as innovation policy and data-driven medicine have become the key framings.  
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Biomedicine is future oriented and promissory; it comes with expectations of better 
treatments, more accurate diagnostics and prevention of diseases (see, e.g., Hamburg & 
Collins, 2010; Hood & Friend, 2011; Swan, 2012). Indeed, many STS studies on cutting-edge 
biomedicine and other emerging technologies have deployed expectations, hypes, hopes, and 
promises as analytical concepts (e.g., Borup et al., 2006; Brown, 2003; Brown & Michael, 
2003; Fortun, 2008; Fujimura, 2003; Hedgecoe, 2004; Helén, 2013; Novas, 2006; Sunder 
Rajan, 2006). These studies emphasize that impressive advances in high-tech medicine are 
essentially based on their “power to raise hopes for new cures and better life in people” 
(Helén, 2004, p. 4). In this paper, we study the making of a medical future in the activities 
done to advocate for personalized medicine in Finland during the past decade.  
In the wake of the Human Genome Project (HGP), great expectations were attached to 
human and medical genomics. A decade after the completion of HGP, fulfilment of the 
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promises has been repeatedly postponed (Burke et al., 2010; Guttmacher & Collins 2005; 
Lander 2011). Still, the expectations should not be considered mere hype. As many studies 
have pointed out (Borup et al., 2006; Brown & Michael 2003; Fujimura, 2003; Helén, 2013; 
Sunder Rajan, 2006; Van Lente, 2012), expectations make things happen. They have the 
power to direct interests; they justify certain R&D projects or programs and make them 
attractive to funding institutions and investors. Expectations point out certain directions and 
paths for the future and, while doing so, reduce uncertainty. They also have the power to 
coordinate, as they bring actors, institutions, and resources together; organize practices and 
communities; and keep networks wired.  
Jasanoff and Kim (2009; 2015) use the concept of sociotechnical imaginaries to 
capture the relationship between social expectations and the development of science and 
technology. The concept refers to “collectively held, institutionally stabilized, and publicly 
performed visions of desirable futures, animated by shared understanding of forms of social 
life and social order attainable through, and supportive of, advances in science and 
technology” (Jasanoff, 2015a, p. 4). Jasanoff (2015b, p. 322) suggests that empirical analyses 
of sociotechnical imaginaries should be focused on “where transformative ideas come from, 
how they acquire mass and solidity, and how imagination, objects and social norms—
including accepted modes of public reasoning and new technological regimes—become fused 
in practice”. We conceive of personalized medicine (see ESF, 2012; Tutton, 2014) as a 
sociotechnical imaginary of contemporary biomedicine that labels the expected changes. 
Personalized medicine is what is to come and what needs to be acted on for societies in 




The imaginary of personalized medicine is a landscape in which medical genomics is 
assembled, policies are shaped, and scientific endeavours are carried out, both in Finland and 
elsewhere. We analyse how this sociotechnical imaginary is fused in practice by studying 
Finnish strategies that pursue the promises of genomics and personalized medicine. Our 
article contributes to the analyses of sociotechnical imaginaries (Jasanoff & Kim, 2015) and 
the discussion about hype and expectations surrounding cutting-edge technoscience (Borup et 
al., 2006; Brown, 2003; Brown & Michael, 2003). We focus on the practical dimensions and 
measures by which the imaginary is promoted and maintained. Jasanoff (2015a, p.10) remarks that the 
“mechanics of the interconnections between technoscientific and political practice have not been 
articulated in detail or systematically”, especially not in relation to innovations. In this paper we show 
that national strategies perform and produce visions that are mutually constitutive with the 
sociotechnical imaginary (see Jasanoff 2015a, p. 11, 14). Our empirical case is an excellent example 
of such co-constitution because the promotion of personalized medicine is an intensely state-driven 
and national endeavour in Finland. We also contribute to the discussion on expectations by analysing 
how a sociotechnical imaginary moulds over time.  
The train of thinking for our study is as follows: Surely, expectations shape practices within the 
sociotechnical imaginary of personalized medicine. They have the power to modify how present 
resources are reconfigured and reorganized to point toward a particular future and even to mobilize 
that future today (Brown, 2003, p. 5). However, the power of expectations is not merely performative 
(cf. Borup et al., 2006; Van Lente, 2012). To be effective, expectations need to be articulated through 
and embedded in practical measures for pursuing personalized medicine in concrete ways and in 
actual political, economic, medical science, and health care settings. We analyse the performative and 
practical aspects of our case with the help of policy framing analysis (e.g. Fischer, 2003; Hajer, 2003, 
Schön & Rein, 1994; for an overview, see van Hulst & Yanow, 2016) By framing, we refer to an 
interpretative scheme for problem-setting and sense-making in policymaking and governance. We talk 
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of framing instead of frames as we want to emphasize the processual and constructive character of 
articulation of meanings, problems, values and agendas in policy-making (van Hulst & Yanow 2016). 
Following Schön and Rein (1994), we make a distinction between two levels of framing upon 
expectations. The first level–rhetorical framing–comprises of general schemes of persuasive 
argumentation that describe and organise how the expectations, promises and advocacy of 
personalized medicine are attached to certain objects, objectives, activities, and actors in a 
consistent and justifiable way. The second level of framing –action framing- informs more 
directly policy programs and implementation. Within action framing, specific expectations 
and practical steps and demands for achieving personalized medicine are defined and outlined. 
Altogether, the concept of framing enables us to grasp the practical or even material side of 
the sociotechnical imaginary of personalized medicine. With the help of the concept we can 
analyse how reasoning, strategies, and practices of implementation are connected. In 
addition, framings allows us to see the dual nature of the practice of putting expectations into 
action: they work both to make the future and to keep up expectations.  
Expectations attached to biomedicine have to be constantly maintained and iterated by 
means of science, politics, administration, and commerce. Such pursuits to govern and 
maintain multiple expectations are oriented toward a future that is not conceived of in terms 
of progress but rather as opportunities involving unpredictability and uncertainty. They 
designate practices to keep the future open by creating prospects and by pointing out and 
mobilizing opportunities and resources that biomedical R&D, clinical care, business, health 
care management, policymaking, and even personal self-help may utilize (Helén, 2013).  
When scientific, administrative, political, and business-making etc. practices search 
for, open up, and create opportunities and harness the potential for, for example, personalized 
medicine they bring together many kinds of stakeholders and actors to pursue biomedical 
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innovations in global and local settings. In a wide range of studies on public policy and 
administration, organizations, and corporate management, governance has become a nearly 
catchall concept to refer to such activities. By governance, many scholars emphasize the 
processual character and open-endedness of policymaking, management, or organization 
reforms. It means practices of governing by which the interests, goals, activities, and powers 
of multiple stakeholders are managed, balanced, and combined in the process of making and 
executing a policy or a reform (e.g., Bevir, 2012). Constant evaluation of the process and its 
achievements and outcomes as well as readjustment of the objectives are also seen to 
characterize governance (e.g., Jessop, 1998; 2002). Practices to maintain the promise of 
personalized medicine share many of these features and, from the perspective of governance 
studies, they can be seen as governance of innovation. 
Recent literature on innovation governance (e.g., Deschamps & Nelson, 2017) 
emphasizes systems, models, leadership, and top–down management of innovative activities. 
Our study points to a somewhat different direction. Practices and rationales promoting 
personalized medicine entwine and enmesh multiple activities with each other, such as 
business, from financing to marketing, resource and personnel management, scientific 
research, product development, consulting, and public governance and policymaking, while 
seeking to manage many sorts of expectations. This kind of innovation and technology 
governance has a particular feature—namely, it involves experimenting with existing 
epistemic, professional, institutional, political, legal, administrative, and business orders 
(Helén 2013). By pointing this out, we want to emphasize that practices dealing with the 
future include unpredictable and unintentional elements..  
In the domains of medicine and health care, the mentioned practices of governance 
manifest themselves by, for example, endless rearrangements of environments and 
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assemblages of biomedical science, medical business, and clinical care in local, national, and 
transnational settings. In this paper, we take a closer look at this particular configuration by 
analysing how governance of and by expectations work and configure in pursuits to sustain 
and promote medical genomics under the imaginary of personalized medicine in Finland. In 
particular, we are interested in how such governance reconfigures the sociotechnical 
imaginary. We study actual strategies, “roadmaps”, proposals for and projects involving 
experimentation, iteration and implementation of techniques, and practices of the future 
medicine in Finland, with a focus on reasoning over the objectives, milestones, measures to 
be taken, issues to be improved, and resources to be mobilized for becoming of personalized 
medicine. In particular, we study the framings within which expectations about the future of 
personalized health care are aligned with the ongoing creation of large depositories of digital 
health data.  
The performative effectivity of a sociotechnical imaginary requires practical 
maintenance. We conceive of the efforts to advance personalized medicine as such 
maintenance. Through our analysis, we want to back up two claims about expectations as 
related with governance and policy-making on biomedical technology. First, in practices of 
promoting and seeking opportunities to advance personalized medicine, sustaining prospects 
is a crucial task that is seemingly more important than the actualization of promises as actual 
outcomes, including scientific results or new health care products. Second, our case shows 
that such maintenance requires the reshaping of expectations, the readjustment of prospects, 
and setting them in new contexts with new alliances. Thus, the actual work—both 
performative and practical—upon the expectations for personalized medicine constantly 
redefines the sociotechnical imaginary itself.  
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Our paper unfolds as follows: In the next section, we introduce the data on which our 
analysis is based on and our research methods; after that, we outline the Finnish strategies to 
promote medical genomics and personalized medicine during the past decade. In Section 4, 
we analyse the currently predominant frames of reasoning for promoting personalized 
medicine, and Section 5 focuses on the practical implementation required to make 
personalized medicine and its benefits happen. In the concluding section of the paper, we 
discuss the characteristics of governance of biomedicine in light of our case, Finland. We 
emphasize that the practices and the rationale of governance support and maintain the 
sociotechnical imaginary of personalized medicine by modifying and gradually changing it. 
2. Materials and Methods 
The research material analysed for this article consists of (a) the main Finnish strategy 
papers and reports that outline and evaluate policies related to biomedicine and health 
technology from 2005 to 2016 (n = 13) (see figure 1); (b) press releases and news posts 
related to the strategies, biobanks, and the genome centre in Finland (n = 9) from 2014 to 
2017; and (c) presentation slides by different stakeholders and field notes from seminars and 
events concerning health technology, biobanks, and genomics from 2013 to 2017 (n = 18). 
The analysed strategies represent the most influential and cited policy frameworks that are 
guiding the development of national infrastructure and strategic funding. In these texts, the 
future of Finnish health care, medical genomics, and biomedicine are envisioned from 
scientific, political, administrative, medical, and commercial perspectives. The main corpus 
of the strategies analysed comprises documents published from 2013 to 2017. Our analysis of 
the documents showed that that the gradual shift of emphasis from health to wealth during 
this time—which we identify in our analysis—became more intensified and apparent in the 
strategy and policy papers. The main publishers of these strategies were the Ministry of 
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Education (ME), the Ministry of Social Affairs and Health (MSH), and the Ministry of 
Economic Affairs and Employment (MEE).  
We collected and utilized the other two types of materials only from the period of 
2013–2017 to illustrate our point and give further depth to our analysis. We used press 
releases and news posts from the Internet related to the publishing of the strategies and 
reports or those published by Finnish biobanks and key funding agencies to describe and 
promote the Finnish health business and ecosystem (such as www.finlandhealth.fi and 
www.sitra.fi). These posts and the presentation slides used in seminars and events were 
collected from the Internet, or notes were made from them along with participant 
observations. We have been following the field since the early 2000s in Finland, and our 
analysis is informed by our experience and different projects in which we have been involved 
(see Lauss et al., 2011; Lehtimäki et al., in press; Tupasela et al., 2015). In these projects, we 
have followed closely the development of biomedicine, biobanking, and medical genomics in 
Finland. We have, for example, participated in seminars, events, and meetings related to the 
topic, where we have listened to presentations by different stakeholders and made field notes. 
The empirical material forms a corpus that represents the official Finnish strategy framework 
as well as how stakeholders such as biobanks and funding agencies reproduce the framework 
in their own materials and presentations.  
First, we read through all of the strategy papers and analysed them thematically 
through inductive qualitative content analysis. Then, we constructed an analytical timeline 
that describes how the overarching imaginary of personalized medicine was presented and 
took new forms in the material. The timeline also points out what kind of promises and 
expectations were articulated, and on what the expectations were placed in each phase or 
strategy. From this, we identified two recurring general framings that featured a distinctive 
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rhetorical style and argument: innovation policy and data-driven medicine.  Within the 
innovation policy framing, the expectations of personalised medicine were primarily 
associated with economic value, growth and competitiveness. Data-driven medicine framing 
highlights the possibilities of public registers, databases and digitalisation to enhance 
personalised medicine and presents these resources as unique elements of Finnish society.  
Both of these rhetorical framings became more intensified and prominent from 2013 onward.  
As we are particularly interested in the practices required to achieve personalised 
medicine, we also examined more specific expectations and identified three action framings 
that apply to domains of both innovation policy and data-driven medicine: Centralization of 
data management, modification of clinical and administrative practices to serve data 
collection, and creation of enabling regulation. Both levels of framing we found, cover both 
performative and practical aspects of sustaining personalized medicine. Within the framings, 
not only visions and objectives are created and reasoned over, but also concrete measures and 
action plans are outlined and discussed. After identifying the framings in the strategy papers, 
we applied them on the press releases, news, and seminar and conference presentations, and 
we found out that the two-level framings were present in them, too.   
Our analysis focuses on Finland, but similar strategies to harness the potential of 
genomics are being developed in other countries as well, for example in Sweden (Cool, 
2016), Great Britain (https://www.genomicsengland.co.uk; 
https://www.gov.uk/government/publications/life-sciences-industrial-strategy), Singapore 
(Ong, 2016), Canada (http://www.genomecanada.ca), and Denmark (Ministry of Health 
2017). Thus, the Finnish case illustrates a more general tendency to attribute economic value 
to population, genomics, and health data.  
3. National Strategies: Creating Value for Science, Health Care, and Commerce 
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Before going into the framings, we first describe the major strategies and milestones 
from the past decade (see Figure 1). The first strategy papers in our material formulated 
genomics as a rising field with huge scientific and medical potential. Biobanks were regarded 
as offering a practical possibility to enhance genomic research and medicine, and preparation 
for a biobank act started in 2006. Concomitantly, up until 2013, expectations of personalized 
medicine were placed on biobanks and biobank networks, which were seen as the platform on 
which to build up personalized medicine. After years of preparation, the Biobank Act (2012) 
was passed to respond to “an increased interest in the potential offered by biobanks” (MSH, 
2011b). After 2013, when the act was first enforced, 11 biobanks meeting the requirements of 
the law have been founded. Two of them have since merged, and the latest biobank included 
in the register is the first private biobank in Finland. While some biobanks have operated 
since 2014, many of the biobanks have only started to collect new samples during the last 
year or have not yet begun to collect samples.  
 




The visions of advancing personalized medicine through biobanks have changed 
considerably, even before the initial visions have been concretely implemented. The earlier 
pursuit of covering Finland with regional biobanks linked to university hospitals and hospital 
districts has been replaced by a vision of a “Biobank Finland”. Two years after the 
registration of the first biobanks, an expert group was appointed to evaluate the possibility of 
integrating the biobanks. The objective of the group’s report on integration was to assess the 
nationwide coordination and integration of Finland’s biobanking resources to optimize the 
realization of value for science, health care, and commerce. In practice, the report and the 
discussions leading to it were looking for ways to either merge or create tighter and more 
standardized cooperation of biobanks that would result in the forming of the legal entity—
"Biobank Finland”—that could better serve the needs of industry and research groups in 
gaining access to data. The expert group formulated the rationale behind the change in the 
following way: 
. . . leveraging the full potential of biobanking in Finland as a national resource will 
only be realized if individual biobank resources are integrated as parts of an 
overarching ecosystem that, by virtue of creating interoperability, results in critical 
mass. (MSH, 2016b) 
Parallel to the developing of biobanking, a proposal for a national “genome strategy” 
was published in Finland in the spring of 2015. Its aim was to set “key measures for ensuring 
that, by 2020, genomic data will be effectively used in health care and in the promotion of 
health and wellbeing” (MSH, 2015, p. 3). The strategy proposal presented visions of how to 
harness the potential of genomic data in Finland. It was the result of a collaborative process 
involving an appointed working group and workshops open to medical, scientific, 
administrative, and commercial stakeholders. The preparation of the strategy was initiated 
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and backed up by the Ministry of Social Affairs and Health and the Finnish innovation Fund 
Sitra, an independent fund reporting to the Finnish Parliament. Sitra’s mission is to invest in 
and direct efforts aimed at “building a successful Finland for tomorrow” (www.sitra.fi). 
The initial aim and tight schedule of the strategy process were planned to coincide 
with the forming of a new government, and the hope was that the strategy would be 
integrated into the government programme. However, the strategy was left out of the 
programme, to the disappointment of the actors involved in the drafting process. Despite the 
setback, the strategy was kept alive and lobbied for, and a year later, government funding was 
directed to establishing a “national genome centre”. In the Genome Strategy, such a centre 
was identified as a major milestone. 
A government statement stated: 
A Genome Centre will be established in Finland, aimed at developing Finland into a 
pioneer and internationally desired partner in health care, high-level research and 
global business utilizing genome data. Public biobank activity will be enhanced by 
standardizing operating methods and ensuring effective cooperation with the Genome 
Centre. (Finnish Government, 2016) 
The Genome Strategy and the genome centre are part of the current future visions of 
biomedicine, and articulate the imaginary of personalized medicine. The imaginary is built on 
preceding visions (see Jasanoff & Kim, 2015) and expectations of Finnish medical genomics, 
biobanks, and biomedicine in general (see Tupasela, 2006), but it also promotes an idea that 
biobanking is not enough for achieving personalized medicine. The Genome Strategy is 
closely linked with other strategic endeavours in Finland that are implemented and revised 
simultaneously, and they are pushed and supported by the same actors. Thus, the strategies 
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are interconnected. The other main endeavours today are the Health Sector Growth Strategy 
(MEE, 2014), the secondary use of social and health data legislation (MSH, 2014), and plans 
for a national Digital Health HUB (Sitra, 2016). The Health Sector Growth Strategy (MEE, 
2014; 2016) is an overarching policy framework that places high expectations on genomic 
data and personalized medicine. It emphasizes Finland’s potential to become a forerunner and 
internationally attractive partner for global business, cutting-edge research, and health care 
utilizing genomic knowledge. Additionally, it states that strong national coordination and 
common infrastructures and institutions are needed for full-scale utilization of genomic 
knowledge and biobank resources.  
While the new social and health data legislation would make it possible to reuse 
health and social data, the HUB would collect and distribute health, social, and welfare data 
from a variety of public databases. The HUB is also planned to function as a single access 
point to the data that serves medical research and development—both public and private, 
scientific or commercial—from Finland and abroad. The plans envision that the biobanks and 
genome centre would also be connected to the HUB, but simultaneously, there is a 
considerable lack of clarity about what this would mean in practice. 
As 2020 approaches, the realization of the vision of personalized medicine and 
fulfilment of the promises of medical genomics are increasingly being directed by ideas and 
projects in the national innovation and growth strategies. As the former flagships, biobanks 
are still part of these new visions, but they are now expected to form an integrated entity and 
be more closely connected to the forthcoming Genome Centre, the digital health HUB, and 
even a Comprehensive Cancer Centre (FICAN), which received funding in the same package 
with the Genome Centre and biobanks in 2016. In biobanks’ current state, their potential is no 
longer regarded as being enough to sustain expectations and create a new competitive edge. 
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4. Framing the Promise 
A sociotechnical imaginary like personalized medicine requires framings to become 
effective and “fused in practice” (Jasanoff, 2015b, p. 322). The strategy papers we analysed 
provide two predominant framings for the prospects of genomics as personalized medicine in 
Finland. They reflect changes in the reasoning by which medical genomics is promoted. The 
first framing is innovation policy, which emphasizes economic and commercial aspects of 
medical genomics, and the second one is data-driven medicine. Currently, the realization of 
the promise hinges less on biomedical research and usage of tissue samples, and more on 
competitive usage of health related data.  
Already in the early 2000s, the advocates of medical genomics presented research as 
an important element of the Finnish “knowledge-based economy” and “innovation system”, 
and the makers of innovation policy considered medical genomics to have considerable 
business potential (Snell, 2009; Tupasela, 2006). At this point, much attention was given to 
scientific potentials, future health care, and public health at the side of this commercial 
potential (Käpyaho et al., 2004; Palotie & Peltonen-Palotie, 2004). However, during the past 
decade, the innovation policy framing has intensified and slowly overshadowed the 
justifications and rationales related to the advancement of biomedical science and public 
health. Within the innovation policy frame, Finland is seen to have assets that give Finnish 
researchers, research institutions, and companies an advantage over their competitors abroad. 
Among them are the unique genetic makeup of the Finnish population, extensive and 
systematic electronic patient records from public health care, electronic national population 
and health registers, cutting-edge medical genomics with advanced biobanks and biobank 
legislation, a public health care system, and popular trust in authorities and medical science 
(MSH, 2015; Sitra, 2015). According to this intensified innovation policy rationale, these 
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factors make Finland an environment for biomedical R&D that cannot be found anywhere 
else in the world—“your test bed for research and medical innovation” (Sitra, 2015). 
Finland’s assets are primarily seen in terms of commercial potential and prospective 
economic gain. The “uniqueness” of the Finnish R&D environment is considered—and 
hoped—to attract international pharmaceutical and other medical enterprises and investors, 
which would increase business opportunities for Finnish researchers, companies, and start-up 
entrepreneurs. For years, innovation and commercial potential have been present in the 
development strategies of genomics, biobanks, and personalized medicine; however, the 
innovation policy framing has previously complemented health and social welfare objectives, 
as an R&D policy definition by the MSH in 2011 outlined: “Reinforcing the foundation for 
the welfare of a socially sustainable society, promotion of equal treatment, and a healthy and 
safe living environment are also the main strategic goals in R&D&I” (MSH, 2011a). 
In the proposal for the Genome Strategy (MSH, 2015) and in the Health Sector 
Growth Strategy (MEE, 2014), the expectations for personalized medicine are articulated 
more explicitly and concretely through innovation policy and commercial framing than in 
regards to public health and health care. These documents are emblematic of the trend in the 
Finnish discussion of justifications related to science and health care being eclipsed by 
economic and business rationales. Simultaneously, the producer of the strategies changed; 
whereas it was Ministry of Education from 2005 to 2007 and the Ministry of Social Affairs 
and Health from 2007 to 2011, it is nowadays the Ministry of Economy and Employment. In 
the current frame of innovation policy, plans to develop biobanks, genomics, and high-tech 
medicine are aimed at making the “innovation ecosystem” of Finnish biomedicine more 
efficient and vibrant. As a result, both the scientific and—in particular—commercial potential 
of medical R&D could be actualized, and the advantage over competitors would not be lost. 
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In particular, the idea of the national HUB facilitating the circulation of Finnish health data is 
embedded in a commercial rationale. The HUB is thought of as a way to provide international 
pharmaceutical corporations and other medical enterprises with easy access to all Finnish 
health databases, collections of human tissue samples, and related patient data, which would 
boost collaboration in biomedical R&D between Finnish expert institutions and international 
business partners. Thus, the development of infrastructure for biomedical research is driven 
by a focus on the economic and commercial prospects of science. This has been a significant 
policy framing of genomics, biobanks, and biomedicine in many countries for two decades, 
starting from deCode Genetics Ltd and the Health Sector Database in Iceland (Fortun, 2008; 
Ong, 2016; Sunder Rajan, 2006).  
These Finnish strategies not only define the expectations of biobanks, medical 
genomics, and biomedical research in terms of innovation policy and commercial prospects 
but also entwine this framing with an understanding of genomics as part of data-driven 
medicine. This is the second current framing of the promise of personalized medicine. When 
biobanks were envisioned, planned, and discussed in different countries at the end of the 
1990s and the early 2000s, they were primarily seen as tissue collections serving large-scale 
DNA sequencing (e.g., Palotie & Peltonen-Palotie, 2004). Parallel to the actual efforts of 
founding and maintaining biobanks and biobank networks during the past decade, the focus 
has shifted from them being depositories of tissue samples to being digital databases to 
enable the combination and circulation of data from tissue sample collections, patient records, 
and population registers (NAS, 2011; Weber, Mandl, & Kohane, 2014; on a similar tendency 
in life sciences in general, see Leonelli, 2016). Likewise, molecular biology is being eclipsed 
by bioinformatics as a key technology of medical genomics (Douglas, 2014; Suárez-Diáz, 
2010; Zerhouni, 2005). This trend is partly a result of the fascination of influential advocates 
of biomedicine in Big Data and rapid advances in IC technology for computation and 
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management of digitalized data (e.g., Hood & Friend, 2011; Topol, 2012). As a result, 
genomics, with its large-scale data-mining projects, has become a part of data-driven 
medicine; consequently, the sociotechnical imaginary of personalized medicine has been 
almost completely coloured by expectations attached to ICT capacity to collect, manage, and 
compute more kinds of health-related data (e.g., Swan, 2012). 
Development in Finland has followed a similar path. The establishment of Finnish 
biobanks, building up of the national health record archive Kanta, and launching of projects 
for translational genomics were parallel processes in the early 2010s. They have been 
directed by a rationale according to which developments in medical research and care 
inevitably lead toward data-driven medicine. This is expected to improve clinical care and 
prevention, increase the cost-effectiveness of health care systems, and provide more precise 
and patient-centred medical knowledge. In congruence with the new focus on the promise of 
personalized medicine, the strategy papers have redefined the assets and competitive 
advantages—both scientific and commercial—Finland has in the global field of medical 
genomics. Framed by the expectations attached to data-driven medicine, well-maintained 
electronic patient registers, digitalized hospital data archives and national health and 
population registers that cover many decades are now seen as the specific features of the 
Finnish medical R&D environment.  
Finland is considered to be in an especially good position as a leading country in the 
so-called personal health care research. Research and know-how are at a high level 
and have available globally unique comprehensive databases about national health. 
This potential should be utilised. (MEE 2014, 3) 
Furthermore, the extensive possibilities to carry out combinations of biological data 
and patient data in a smooth and accurate manner make Finland “unique”. This rise of the 
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importance of data is already reflected in the need to re-evaluate the Biobank Act from the 
day it was put into force. The legislation process had taken such a long time that when the 
law was finally enacted, it did not meet the needs anymore. For example, it was considered 
too sample centric, which also formed a background to the different projects, initiatives, and 
openings done in the name of making Finnish health data available (Tupasela et al., 2015).  
The advocates assume that Finnish biobanks and medical genomics are attractive to 
international scientific and commercial partners due to the availability of “real-life data”. 
Furthermore, Finland’s competitive advantage does not lie merely in data collections per se 
but in the expertise in managing of such data. Scientific and commercial partners are believed 
to be interested in combined datasets. Finnish biobanks and the medical genomics research 
community have developed data-management practices that combine sample management, 
bioinformatics, and administrative expertise. Demand for such expertise in digital data 
management has grown immensely, as research in life sciences and biomedicine has become 
oriented toward handling and mining large datasets with the help of ICT (see Leonelli, 2013; 
2016). 
A key claim in the promotion of genomics-based personalized medicine is that health-
related data is both unique in their extent and quality and easy to access and manage for 
R&D purposes in Finland. The high hopes and big claims related to the Finnish health “Big 
Data” are embedded in a long history of public authorities keeping population and health 
registers and statistics, extending back to the 18th century. The first computerized national 
disease register, the Cancer Register, was established in 1952. Statistics Finland and the 
National Institute of Health and Welfare (THL), as public authorities, facilitated the use of 
register data in a wide range of medical and social studies during the latter half of the 20th 
century (Gissler & Haukka, 2004). In addition to the national databases, public hospitals and 
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health care districts have systematically kept patient record archives since the early 20th 
century, and the majority of patient records and data about medical care have been stored in 
electronic form for three decades in Finland. THL and the Social Insurance Institution of 
Finland have compiled data from hospitals, health care centres, health insurance 
compensations and pensions, and prescriptions, and the national patient record and 
prescription archive Kanta has been in operation since 2010. This vast amount of health data 
that has already been collected in Finnish public databases, combined with the data in 
biobank depositories, is seen to be Finland’s main asset in making the Finnish biomedical 
“innovation ecosystem” competitive and attractive to collaborators and investors.  
In the 2010s, the term national treasure, referring to public health databases, spread 
throughout the biomedical and genomic strategies. Strategic documents attempted to show 
what different stakeholders should do to actualize the scientific, medical, and above all, 
commercial potential of the Finnish health data to transform “a pile of ore into a treasure” 
(Hämäläinen, 28.10.2016). Such a metaphor creates an association between public health 
databases and Finnish natural resources, like forests being “green gold” to the forestry 
industry, which has been the backbone of the Finnish export economy since WWII. In the 
sociotechnical imaginary of data-driven personalized medicine data, people—or the 
population providing biological and health data—and the public institutions that generate and 
collect that data are considered natural resources that stakeholders from biomedical business 
can appropriate and utilize. Within the transnational field of personalized medicine, the 
Finnish imaginary is emphatically framed as a national effort. 
5. Framing the practical measures  
The strategies and roadmaps include many practical measures to harness this national 
treasure. Despite the expectations, the Finnish health data reservoir has not been fully 
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appropriated. On the one hand, the potential for combination of data from different digital 
databases and depositories is seen as enormous. On the other hand, only a fraction of this 
potential is currently utilizable. Consequently, the standardization, coverage, and 
effectiveness of Finnish health care institutions in collecting, managing, and circulating 
patient and “-omics” data should be vastly improved. Specifically, “the full potential of 
biobanking in Finland can only be realized if the three requirements outlined above can be 
met: standardization/integration, annotation with EHR/EMR [electronic health 
record/electronic medical record], and funding to attain critical mass” (MSH, 2016b, p. 5). 
The roadmaps outlined in the strategy papers consist of three main elements that we 
identified as action framings: centralization of data management, modification of practices to 
serve data collection, and the creation of enabling regulation. First, almost all papers share 
the view that resources need to be concentrated into large units to realize their full potential—
whether through the integration of biobanks or the centralization of data management, as we 
described above. Centralization does not mean closing down regional and other biobanks but 
coordination of their data depositories, harmonization, and unified access procedures for the 
biobank data as well as appropriation, circulation, and combination of the data with other 
health databases under a common service provider and the national Health Data HUB. These 
plans are attempts to achieve a main goal of the health sector growth strategy (MEE, 2014), 
namely enabling easy access to personal health data and patient documents for R&D 
purposes: “The plan is to harness these data resources, which are unique by international 
standards, for more extensive use and utilization closer to the individual. Information from 
different sources should be offered smoothly, following the so-called one-stop shop 
principle” (MEE, 2016). 
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The second action framing concerns health care institutions. The visions of data-
driven personalized medicine and policy promoting view the public health care system from a 
new perspective. Regarding innovative biomedical R&D, hospitals, health care centres, and 
clinical laboratories are primarily important and valuable as suppliers of patient data and as 
sites for experimentation and trials. To enhance this value potential, health care institutions 
have to be reformed to become compatible with the “health sector innovation ecosystem”. 
The strategy papers and discussions on the topic have proposed many such changes. Clinical 
practices and information systems are urged to be reconfigured so that data collection, 
management, and circulation to the data hubs would become a key task vis-á-vis patient 
treatment (MSH, 2014). For example, hospitals involved in regional biobanks have 
complemented their daily clinical routines with practices to inform patients about biobank 
participation, collect consents and tissue samples, and submit samples and patient data to the 
biobank. More generally, modifications to information-processing systems and clinical 
inscription practices have been demanded and initiated throughout the Finnish health care 
system to make them compatible with large-scale data collection, circulation, and 
appropriation for data-driven personalized medicine.  
Strategy papers and advocates of personalized medicine have also suggested that 
hospitals and health care centres be “iterated” to be more adaptive to experiments that 
“translate” genomics, advanced data analytics, or novel digital health technology into clinical 
practice. Many projects responding to this call are already under way. For instance, the 
GeneRISK project provides research subjects with a personal genetic risk score for a 
cardiovascular event by combining genomic and other data. In some cases, the risk score is 
also mediated to electronic patient records in health care (http://www.generisk.fi). The 
extension of clinical trials and data appropriation to basic health care centres is planned and 
being prepared in collaboration with medical companies as a part of the Health Capital 
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Helsinki initiative (http://www.healthcapitalhelsinki.fi/en/). In addition, Uusimaa Health Care 
District (HUS) is creating an “ecosystem” of digital health technology and opening up 
university hospital clinics to private companies to develop and test their data-management 
technologies (Tekes, 2017). In these exemple projects, existing institutions and medical 
practices are captured by experimentality as they are modified to adopt tasks and procedures 
that serve the development of and experimentation with data-driven medicine. 
Finally, many strategy papers and statements by the advocates of personalized 
medicine express that ethical procedures, regulations, and legislation related to the collection, 
storage, and appropriation of health data need to be updated to enable more intensive 
utilization of Finnish databases and biobanks by academic and commercial R&D. This 
demand for enabling regulation is the third action framing. As often repeated in the Finnish 
discussion, “There is a danger that huge investments in health which Finland has made during 
the past decades will become futile if legislations and [regulative] structures are not 
determinedly developed from a perspective of research and its commercialization” (MEE, 
2014). 
The enabling regulation to create and sustain competitiveness is an important element 
of the innovation policy. An example of this is the legislation for the secondary uses of social 
and health care data, which is aimed at supporting the building of the national health data 
hub. The legislative process was hurried, and the law is expected to be put into force in the 
beginning of 2018 (MSH, 2017).  
6. Discussion 
We have analysed how medical genomics, biobanks, and biomedicine have been 
promoted in Finland within a sociotechnical imaginary (Jasanoff, 2015a) of personalized 
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medicine. We identified two rhetorical framings within which expectations, pursuits, plans, 
and activities for advancing personalized medicine are connected into a reasonable and 
justifiable endeavour: innovation policy and data-driven medicine. During the past decade, 
these framings have intensified and become predominant. First, the promise of personalized 
medicine today is defined more in terms of wealth than health. The visions of advances in 
medical science and care have been eclipsed by expectations of business opportunities and 
commercial collaboration with Big Pharma and international investors. Second, the focus in 
promoting the future of genomics-based personalized medicine has shifted from molecular 
biology and tissue samples to the management of a variety of health-related data, of which 
biological specimens are just a part. 
These tendencies have not merely grown out of the dynamics of biomedicine. In this 
paper, we emphasize that these shifts are being initiated and facilitated by reasoning, 
practices, pursuits, and tinkering required to sustain the promise of personalized medicine. In 
addition to the visions of the future, the sociotechnical imaginary of personalized medicine 
and the expectations it carries are kept alive and credible not only by the grand visions of the 
future but essentially by concrete strategies, plans and roadmaps, alliance-making, and 
projects in which new technologies and practices are experimented with, demonstrated, and 
implemented. We identified three action framings that articulate, in our case, the practical 
aspect of sociotechnical imaginary and expectations. They are particularly important because 
they initiate and steer activities that maintain the expectations about personalized medicine by 
seeking opportunities, harnessing prospects, and mobilizing resources and potential. In 
addition, the action framings and the practices they promote or are associated with include an 
aspect of experimenting with existing political, legal, economic, epistemic-technical, 
professional, and even ethical orders, and they deal with uncertainty and even the unknown 
associated with experimenting (Helén, 2013). 
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Our analysis shows that defining concrete objectives, roadmaps, and milestones; 
demonstrating actual outcomes; and proceeding step by step in a flexible way are core 
characteristics of governance that creates the future of personalized medicine and keeps up 
expectations. To make the vision and promises effective, policy-making ha to attach them to 
concrete projects and plans that may show actual achievements in a reasonable timeframe and 
to actual outcomes that demonstrate advances in personalized medicine. However, the 
outcomes and achievements tend to be secondary and subsumed to the activities of 
maintaining expectations and creating further opportunities ; in other words, actual scientific, 
technological, or clinical advances have primarily a performative value as they testify to the 
emergence of personalized medicine.  
Practices and efforts we analyzed have to be flexible because they hold together great 
visions and concrete strategies, plans for experimentation and implementation and the 
tentative outcomes of R&D or clinical implications. Therefore, governance of and by 
expectations is contextual; it works by iterating and navigating, and it requires improvisation 
and approximations. Consequently, the imaginary of personalized medicine appears to be 
malleable and inclined to permanent redefinition. In the Finnish policy discourse and 
discourse among experts, the core meaning of personalized medicine is detached from 
molecular genomics and biology. Instead, the collection and analysis of all kinds of personal 
health-related data by means of advanced bioinformatics are seen as the key factors in the 
development of more precise and individually tailored medical care. Additionally, the idea of 
biobanks and biobank infrastructures is being replaced by visions of health data hubs and 
their networks. The change of focus in the Finnish discourse is congruent with an 
international trend in the past decade to merge the idea of personalized medicine with the 
idea of data-driven medicine (NAS, 2011; Prainsack, 2017; Swan, 2012; Weber, Mandl & 
Kohane, 2014). The facilitation of access to health databases, creation of opportunities for 
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their wider use, and harnessing of new sources of health-related data have become key 
objectives of promoting personalized medicine—in Finland and elsewhere. 
Our analysis also points out that due to its iterative, flexible and “opportunistic” 
character, promotion of biomedicine is almost inevitably fused with politicization of the 
sociotechnical imaginary of personalized medicine. This does not mean that advocates of 
medical genomics solely lobby politicians and policymakers and try to acquire support and 
financing for biobanks and research projects (cf. Brown et al. 2000). Rather, personalized 
medicine has become an important policy matter and an object of interest to policymakers, 
especially within the realm of innovation policy. Today, expectations regarding personalized 
medicine are not primarily contextualized in the areas of biomedical research and health care; 
instead, the discourse and rationale of innovation policy redefine what personalized medicine 
is, its potential and worth, and how it is discussed. An excerpt from a talk by the minister of 
economic affairs and employment epitomizes the current situation, in which top ministry 
officials, program directors of think tanks like Sitra, and politicians are voicing the objectives 
and value of the creation of a medical future, even though the essential knowledge and 
expertise are derived from practitioners of biomedical science and medical business:  
Finland has invested in health-related science, research and education, as well as to 
research infrastructures and extensive public health care system for decades. Now 
these investments are starting to bear fruit not only in health care but also as a source 
for innovation, business opportunities, jobs and economic growth. . . . Boosting health 
sector growth is one of the key priorities in our overall growth policy. We are building 
on our strengths; thus digital health and personalized medicine are at the core of the 
growth strategy. (Rehn, 2016) 
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In this setting, the collection and management of Finnish health data in and via data 
hub is primarily an economic matter. It is emphasized that facilitating R&D in personalized 
medicine may reduce the costs of public health care and, in particular, create business 
opportunities and alliances that would boost the growth of the Finnish health sector. Today, 
similar economic assumptions underpinning an emerging technology are also common 
elsewhere and in other domains of technoscience (Birch, 2017). In addition, promoting data-
driven personalized medicine is predominantly defined as a national cause. Finland is 
considered to have assets in its population, databases, and public health care system for 
international competition, and such national resources, “a treasure”, should be embraced and 
utilized by national endeavours that would bring together all Finnish stakeholders—
researchers, commercial stakeholders, the state, and local public institutions. 
A key element in the rationale of boosting biomedical innovation is the view that 
Finland needs to “grow into an internationally interesting partner in genomics research and 
genomics-related enterprise” (MSH, 2015, p. 3). Within the innovation policy framing, this 
objective is inseparably political, economic, and scientific (see also Birch 2017; Muniesa 
2017). Our analysis of roadmaps, suggestions, and actions to reach this objective show that 
the iteration, flexibility, and malleability of governance also create tensions, fuzziness, and 
disorientation. This side is indicated in, for example, the often repeated claims or even 
imperatives of Finnish strategy papers and by advocates of personalized medicine that 
everything has to be done fast because “the window of opportunity for exploiting Finland’s 
strengths will be open for a few years at best” (STM, 2015, p. 3). From every corner of the 
Finnish biomedical “innovation ecosystem” arise demands for policymaking on personalized 
medicine to move quickly in removing legislative, regulatory, and ethical obstacles from a 
more extensive collection of tissue samples and health data and from creating wider access to 
and deployment of the Finnish population and health databases. Such a rush is justified by 
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appealing to necessity and urgency to enhance business opportunities and commercial 
collaboration between Finnish stakeholders and international enterprises and investors. 
Although innovation policy for personalized medicine is future oriented, it seems that the 
present moment matters most: it is right now (or never) that the medical future ought to be 
made.  
Besides hurry, politics and policymaking on data-driven personalized medicine are 
characterized by uncertainty and confusion. This is also due to the multitude of parallel and 
overlapping strategies, such as the Health Sector Growth strategy, the Genome Strategy, and 
the legislative reform on the secondary use of data. Despite the roadmaps and action plans 
they have presented in reports and PowerPoint presentations, the stakeholders that 
participated in drafting the plans do not seem to have a clear picture of what actions will be 
taken next or what the outcomes of their strategies will be. Experts attending seminars and 
workshops wonder what exactly the Genome Centre will be, what the role of regional 
biobanks will be, and how the national Health Data HUB will relate to planned biobank 
fusion, and they are worried about the integration of ICT systems for managing health data. 
Discussions on these questions reflect differences of opinion and even disagreements, but this 
is also a sign of genuine confusion about the actual nature, objectives, and benefits of the 
innovation process. Such confusion is fuelled by the fact that attempts to bring genuine 
applications of data-driven genomics and e-health to clinics are experimental and embryonic, 
and the advocacy of personalized medicine appears to be out of step regarding how quickly 
data-driven approaches and techniques can be implemented into the health care system and 
clinical practices. Similar features are found to plague health technology development in 
general, indicating misalignments, confusion and poor functioning of innovation processes 
and milieus (Greenhalg 2018; Lehoux et al., 2017). 
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Our analysis highlights that the practices of governance and policy-making for 
promoting and making up a medical future keep the sociotechnical imaginary malleable. 
Expectations and visions of the future of biomedicine are not rigid and static but are 
continuously under transformation. In Finland, several initiatives and activities in 
biomedicine have been launched under the title of “personalized medicine.” As they are 
carried out, these activities change the very meaning of what the imaginary of personalized 
medicine entails. Internationally, this sociotechnical imaginary is about to be hijacked by the 
growing emphasis on health-related data and digitalization, and the promises of personalized 
medicine seem to be merging with visionary landscapes of the emerging digital data economy 
(e.g., Prainsack, 2017). Also, efforts in Finland to maintain the promise of personalized 
medicine are rearranging the idea and future vision surrounding data-driven medical business. 
The imaginary of personalized medicine is then being deployed to build a future that seems to 
be less about citizens’ health services and more about building a route for Finland to become 
the “Silicon Valley” (e.g., Heino, 2016) of health technology, health data, and medical 
applications of artificial intelligence. Consequently, despite its promises for public and 
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